Fulcrum Therapeutics (FULC) Other Accumulated Expenses (2019 - 2025)
Historic Other Accumulated Expenses for Fulcrum Therapeutics (FULC) over the last 7 years, with Q3 2025 value amounting to $236000.0.
- Fulcrum Therapeutics' Other Accumulated Expenses fell 4100.0% to $236000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $236000.0, marking a year-over-year decrease of 4100.0%. This contributed to the annual value of $463000.0 for FY2024, which is 1691.92% up from last year.
- Per Fulcrum Therapeutics' latest filing, its Other Accumulated Expenses stood at $236000.0 for Q3 2025, which was down 4100.0% from $173000.0 recorded in Q2 2025.
- Fulcrum Therapeutics' 5-year Other Accumulated Expenses high stood at $463000.0 for Q4 2024, and its period low was $9000.0 during Q1 2023.
- In the last 5 years, Fulcrum Therapeutics' Other Accumulated Expenses had a median value of $134000.0 in 2022 and averaged $187578.9.
- In the last 5 years, Fulcrum Therapeutics' Other Accumulated Expenses tumbled by 9328.36% in 2023 and then soared by 417777.78% in 2024.
- Fulcrum Therapeutics' Other Accumulated Expenses (Quarter) stood at $74000.0 in 2021, then surged by 41.89% to $105000.0 in 2022, then skyrocketed by 277.14% to $396000.0 in 2023, then rose by 16.92% to $463000.0 in 2024, then tumbled by 49.03% to $236000.0 in 2025.
- Its Other Accumulated Expenses stands at $236000.0 for Q3 2025, versus $173000.0 for Q2 2025 and $441000.0 for Q1 2025.